Open Long COVID / Post-Acute COVID Sequelae (PACVS) in the Repurposing ExplorerLong COVID / Post-Acute COVID Sequelae (PACVS) hub
Anakinra
Biologic · tier A · 0 trials (0 recruiting) · 15 publications · score 50.0
Nicotine
Drug · tier A · 0 trials (0 recruiting) · 14 publications · score 50.0
Remdesivir
Drug · tier A · 0 trials (0 recruiting) · 14 publications · score 50.0
Sotrovimab
Biologic · tier A · 0 trials (0 recruiting) · 12 publications · score 50.0
Tocilizumab
Biologic · tier A · 0 trials (0 recruiting) · 14 publications · score 50.0
Regdanvimab
Biologic · tier A · 0 trials (0 recruiting) · 6 publications · score 41.0
Creatine
Supplement · tier C · 0 trials (0 recruiting) · 14 publications · score 35.0
N-acetylcysteine (NAC)
Supplement · tier C · 0 trials (0 recruiting) · 7 publications · score 28.0
Tozinameran
Drug · tier A · 0 trials (0 recruiting) · 3 publications · score 28.0
Elasomeran
Drug · tier A · 1 trials (0 recruiting) · 0 publications · score 23.5
Tacrolimus Anhydrous
Drug · tier A · 1 trials (0 recruiting) · 0 publications · score 23.5
Taurine
Supplement · tier C · 0 trials (0 recruiting) · 3 publications · score 17.0
Research map, not treatment advice. Built 2026-10-07.